← Back to all signals
RESEARCH PAPER ANALYSIS

Preliminary evidence for cognitive associations of postural control in older and younger adults, and people with Parkinson's disease.

This multi-site study found group-specific associations between cognitive domains—especially executive function—and quantitative postural sway across sensory standing conditions in people with Parkinson’s disease, older adults, and younger adults, with better executive function unexpectedly linked…

PMID41905336
JournalParkinsonism & related disorders
Publication Date2026-03-26
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

This multi-site study found group-specific associations between cognitive domains—especially executive function—and quantitative postural sway across sensory standing conditions in people with Parkinson’s disease, older adults, and younger adults, with better executive function unexpectedly linked…

WHY IT MATTERS

Research significance

Although it does not identify molecular or druggable targets, the study has translational value for PD by linking cognition to fall-risk phenotypes and supporting sensor-based monitoring and cognitive/rehabilitative interventions to mitigate postural instability.

ABSTRACT

Source abstract

BACKGROUND: Postural instability is one of the most debilitating symptoms of Parkinson's disease (PD). It is also major concern in healthy older adults (OA), contributing to increased fall risk. Cognitive function plays a critical role in postural control. However, little is known about the specific cognitive domains related to postural control in these populations. This study aimed to examine how postural control relates to different domains of cognitive function across varying standing sensory conditions, and how these associations are influenced by age, PD and PD severity. METHODS: A total of 232 participants (127 people with PD (PwPD) aged 69.51 (7.67)), 52 OA (aged 68.78 (7.92) and 53 younger adults (YA) (aged 23.58 (4.02) were assessed across two sites. PwPD were also categorised based on Hoehn and Yahr (H&Y) stage I, II and III. Participants completed cognitive tests and four standing tasks (eyes open/closed, firm/foam surface). Sway measures (area, velocity, jerkiness, root mean square, and frequency) were collected using six wearable inertial sensors. Hierarchical linear regression analysis examined cognitive predictors of sway within each group. RESULTS: Regression analyses revealed group-specific cognitive-postural associations. In PwPD, OA, YA, and H&Y II, better executive function was linked to increased sway outcomes. CONCLUSIONS: Increased sway outcomes may reflect a more flexible, adaptive postural control strategy, while reduced sway outcomes may reflect a more constrained postural strategy linked to poorer cognition. These findings highlight the importance of considering performance on specific cognitive domains, age, and disease severity when assessing postural control and fall risk in OA and PwPD.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic